All In Biotech

Drug Trial Radar · NCT07177209

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

DESCRIBING PRESCRIPTION PATTERNS IN AN ULCERATIVE COLITIS POPULATION AND GENERATING AN UPDATED ULCERATIVE COLITIS TREATMENT PARADIGM

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,000

Actual

Start

Apr 1, 2026

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Conditions

  • Ulcerative Colitis

Interventions

  • Non-Interventional StudyDrug

    As provided in real world practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients that achieve early control of inflammation on conventional therapeutics within 6-24 months of UC diagnosis.Time frame: 6-24 months from UC diagnosis.
  2. Difference in proportion of patients with inadequate control of inflammation (defined as two or more episodes of raised CRP or faecal calprotectin) treated with conventional therapeutics versus treatment escalation 24 months post UC diagnosis.Time frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer

    Tadworth, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.